{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:20:41Z","timestamp":1790385641426,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40262-016-0466-4","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T10:42:06Z","timestamp":1476700926000},"page":"459-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat"],"prefix":"10.1007","volume":"56","author":[{"given":"Bishoy","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry G.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Pile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"issue":"2","key":"466_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","volume":"15","author":"JN Loeb","year":"1972","unstructured":"Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189\u201392.","journal-title":"Arthritis Rheum."},{"issue":"8","key":"466_CR2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","volume":"45","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006;45(8):821\u201341.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"466_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2125.2010.03667.x","volume":"70","author":"B Grabowski","year":"2010","unstructured":"Grabowski B, Khosravan R, Wu JT, Vernillet L, Lademacher C. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol. 2010;70(1):57\u201364.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"466_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0091270010365549","volume":"51","author":"BA Grabowski","year":"2011","unstructured":"Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol. 2011;51(2):189\u2013201.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"466_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2125.2007.03016.x","volume":"65","author":"R Khosravan","year":"2008","unstructured":"Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008;65(3):355\u201363.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"466_CR6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270005282634","volume":"46","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88\u2013102.","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"466_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","volume":"12","author":"MD Mayer","year":"2005","unstructured":"Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22\u201334.","journal-title":"Am J Ther."},{"issue":"10","key":"466_CR8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1055\/s-0032-1321847","volume":"62","author":"XX Liu","year":"2012","unstructured":"Liu XX, Liu RJ, Ding L, Lin YF, Huang NY, Xiao HF, et al. Pharmacokinetics of febuxostat in healthy Chinese volunteers. Arzneimittelforschung. 2012;62(10):463\u20139.","journal-title":"Arzneimittelforschung."},{"issue":"4 Suppl 2","key":"466_CR9","first-page":"S27","volume":"17","author":"T Hosoya","year":"2011","unstructured":"Hosoya T, Ohno I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol. 2011;17(4 Suppl 2):S27\u201334.","journal-title":"J Clin Rheumatol."},{"issue":"9","key":"466_CR10","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0091270008322035","volume":"48","author":"R Khosravan","year":"2008","unstructured":"Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48(9):1014\u201324.","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"466_CR11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202394","volume":"54","author":"H Zhou","year":"2016","unstructured":"Zhou H, Zheng Y, Wu G, Hu X, Zhai Y, Iv D, et al. Pharmacokinetics and tolerability of febuxostat after oral administration in healthy Chinese volunteers: a randomized, open-label, singleand multiple-dose three-way crossover study. Int J Clin Pharmacol Ther. 2016;54(2):115\u201324.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"1","key":"466_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01059343","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Benet LZ, Pagliaro LA. A standard approach to compiling clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9(1):59\u2013127.","journal-title":"J Pharmacokinet Biopharm."},{"issue":"1","key":"466_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02353511","volume":"24","author":"RD Purves","year":"1996","unstructured":"Purves RD. Multiple solutions, illegal parameter values, local minima of the sum of squares, and anomalous parameter estimates in least-squares fitting of the two-compartment pharmacokinetic model with absorption. J Pharmacokinet Biopharm. 1996;24(1):79\u2013101.","journal-title":"J Pharmacokinet Biopharm."},{"issue":"2","key":"466_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clpt.2005.12.076","volume":"79","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. Population pharmacokinetics and pharmacodynamics of febuxostat in a phase III study of patients with gout [abstract]. Clin Pharmacol Ther. 2006;79(2):21.","journal-title":"Clin Pharmacol Ther."},{"issue":"1\u20132","key":"466_CR15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000434633","volume":"96","author":"D Hira","year":"2015","unstructured":"Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96(1\u20132):90\u20138.","journal-title":"Pharmacology."},{"issue":"5","key":"466_CR16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/00498250801956350","volume":"38","author":"M Mukoyoshi","year":"2008","unstructured":"Mukoyoshi M, Nishimura S, Hoshide S, Umeda S, Kanou M, Taniguchi K, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008;38(5):496\u2013510.","journal-title":"Xenobiotica."},{"issue":"9","key":"466_CR17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/jps.2600600909","volume":"60","author":"M Gibaldi","year":"1971","unstructured":"Gibaldi M, Boyes RN, Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci. 1971;60(9):1338\u201340.","journal-title":"J Pharm Sci."},{"issue":"1","key":"466_CR18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(25)20718-2","volume":"251","author":"BC Sallustio","year":"1989","unstructured":"Sallustio BC, Purdie YJ, Birkett DJ, Meffin PJ. Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle. J Pharmacol Exp Ther. 1989;251(1):288\u201394.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"466_CR19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-3565(25)22126-7","volume":"227","author":"PJ Meffin","year":"1983","unstructured":"Meffin PJ, Zilm DM, Veenendaal JR. A renal mechanism for the clofibric acid-probenecid interaction. J Pharmacol Exp Ther. 1983;227(3):739\u201342.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"466_CR20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/clpt.1981.48","volume":"29","author":"JR Veenendaal","year":"1981","unstructured":"Veenendaal JR, Brooks PM, Meffin PJ. Probenecid-clofibrate interaction. Clin Pharmacol Ther. 1981;29(3):351\u20138.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"466_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(03)00020-6","volume":"145","author":"MJ Bailey","year":"2003","unstructured":"Bailey MJ, Dickinson RG. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact. 2003;145(2):117\u201337.","journal-title":"Chem Biol Interact."},{"issue":"8\u20139","key":"466_CR22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, et al. PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004;23(8\u20139):1117\u20138.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"issue":"8\u20139","key":"466_CR23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1081\/NCN-200027381","volume":"23","author":"K Komoriya","year":"2004","unstructured":"Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase\/xanthine dehydrogenase (NPSIXO) in patients with gout and\/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids. 2004;23(8\u20139):1119\u201322.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"issue":"3","key":"466_CR24","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","volume":"278","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278(3):1848\u201355.","journal-title":"J Biol Chem."},{"issue":"6","key":"466_CR25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/15257770802146577","volume":"27","author":"K Okamoto","year":"2008","unstructured":"Okamoto K, Eger BT, Nishino T, Pai EF, Nishino T. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):888\u201393.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"issue":"2\u20133","key":"466_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(93)90201-R","volume":"241","author":"Y Osada","year":"1993","unstructured":"Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993;241(2\u20133):183\u20138.","journal-title":"Eur J Pharmacol."},{"issue":"16","key":"466_CR27","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","volume":"76","author":"Y Takano","year":"2005","unstructured":"Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase. Life Sci. 2005;76(16):1835\u201347.","journal-title":"Life Sci."},{"issue":"8\u20139","key":"466_CR28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","volume":"23","author":"MA Becker","year":"2004","unstructured":"Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004;23(8\u20139):1111\u20136.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"issue":"2","key":"466_CR29","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"466_CR30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol."},{"issue":"23","key":"466_CR31","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med."},{"issue":"3","key":"466_CR32","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916\u201323.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"466_CR33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188\u201394.","journal-title":"Rheumatology (Oxford)."},{"issue":"11","key":"466_CR34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540\u20138.","journal-title":"Arthritis Rheum."},{"key":"466_CR35","unstructured":"Clinical pharmacology and biopharmaceutics reviews of febuxostat. Department of Health and Human Services; Food and Drug Administration (FDA); 2008. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000_ClinPharmR_P1.pdf . Accessed 10 Mar 2016."},{"issue":"7","key":"466_CR36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/13543784.14.7.893","volume":"14","author":"HR Schumacher Jr","year":"2005","unstructured":"Schumacher HR Jr. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs. 2005;14(7):893\u2013903.","journal-title":"Expert Opin Investig Drugs."},{"issue":"12","key":"466_CR37","first-page":"1674","volume":"49","author":"Y Sun","year":"2014","unstructured":"Sun Y, Li L, Tian-yan Z, Lu W. A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patients [abstract]. Acta Pharmaceutica Sinica. 2014;49(12):1674\u201383.","journal-title":"Acta Pharmaceutica Sinica."},{"key":"466_CR38","unstructured":"Sun Y, Li L, Marshall S, Lu W, Xie R. Relationship between the dose of urate lowering therapies and serum uric acid in healthy volunteers and gout patients: a model based meta-analysis (MBMA) [abstract]. Population Approach Group in Europe (PAGE). June 2015. http:\/\/www.page-meeting.org\/?abstract=3513# . Accessed 7 Apr 2016."},{"issue":"10","key":"466_CR39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"466_CR40","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372\u20134.","journal-title":"Rheumatology (Oxford)."},{"key":"466_CR41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/etm.2013.1414","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, Di X, Xu L, Xu J, Yang Y, Jiang N, et al. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med. 2014;7:393\u20136.","journal-title":"Exp Ther Med"},{"issue":"8","key":"466_CR42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623\u201344.","journal-title":"Clin Pharmacokinet."},{"key":"466_CR43","unstructured":"Zyloprim (allopurinol) product information. The Therapeutic Goods Adminstration (TGA). 22 Feb 2016. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=&q=allopurinol . Accessed 10 Mar 2016."},{"issue":"6","key":"466_CR44","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","volume":"76","author":"GG Graham","year":"2013","unstructured":"Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol. 2013;76(6):932\u20138.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"466_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","volume":"44","author":"CG Jennings","year":"2014","unstructured":"Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014;44(1):25\u201330.","journal-title":"Semin Arthritis Rheum."},{"issue":"2","key":"466_CR46","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O\u2019Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412\u201321.","journal-title":"Arthritis Rheum."},{"key":"466_CR47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2318-12-11","volume":"12","author":"RL Jackson","year":"2012","unstructured":"Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients \u226565 years of age. BMC Geriatr. 2012;12:11.","journal-title":"BMC Geriatr."},{"key":"466_CR48","doi-asserted-by":"crossref","first-page":"123105","DOI":"10.1155\/2014\/123105","volume":"2014","author":"AK Tausche","year":"2014","unstructured":"Tausche AK, Reuss-Borst M, Koch U. Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study. Int J Rheumatol. 2014;2014:123105.","journal-title":"Int J Rheumatol."},{"issue":"6","key":"466_CR49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","volume":"17","author":"X Huang","year":"2014","unstructured":"Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679\u201386.","journal-title":"Int J Rheum Dis."},{"issue":"4 Suppl 2","key":"466_CR50","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13\u20138.","journal-title":"J Clin Rheumatol."},{"issue":"4 Suppl 2","key":"466_CR51","first-page":"S44","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S44\u20139.","journal-title":"J Clin Rheumatol."},{"issue":"4 Suppl 2","key":"466_CR52","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/RHU.0b013e31822541d0","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol. 2011;17(4 Suppl 2):S50\u20136.","journal-title":"J Clin Rheumatol."},{"issue":"2","key":"466_CR53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155\u201363.","journal-title":"Am J Med."},{"issue":"12","key":"466_CR54","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;53(12):2167\u201374.","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"466_CR55","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, Group RS. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074\u201380.","journal-title":"Ann Rheum Dis."},{"key":"466_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840","author":"KG Saag","year":"2016","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis Rheumatol. 2016. doi: 10.1002\/art.39840 (Epub 2016 Aug 26).","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"466_CR57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","volume":"38","author":"SL Stocker","year":"2011","unstructured":"Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38(5):904\u201310.","journal-title":"J Rheumatol."},{"issue":"11","key":"466_CR58","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0026-0495(79)90148-3","volume":"28","author":"R Bianchi","year":"1979","unstructured":"Bianchi R, Vitali C, Clerico A, Pilo A, Riente L, Fusani L, et al. Uric acid metabolism in normal subjects and in gouty patients by chromatographic measurement of 14C-uric acid in plasma and urine. Metabolism. 1979;28(11):1105\u201313.","journal-title":"Metabolism."},{"issue":"8","key":"466_CR59","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/0091270006289848","volume":"46","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol. 2006;46(8):855\u201366.","journal-title":"J Clin Pharmacol."},{"issue":"9","key":"466_CR60","first-page":"S102","volume":"52","author":"R Khosravan","year":"2005","unstructured":"Khosravan R, Mayer MD, Wu JT, Josephridge N, Vernillet L. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthritis Rheum. 2005;52(9):S102\u20133.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"466_CR61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clpt.2004.12.059","volume":"77","author":"R Khosravan","year":"2005","unstructured":"Khosravan R, Erdman K, Vernillet L, Wu JT, Josephridge N, Umeda S, et al. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects [abstract]. Clin Pharmacol Ther. 2005;77(2):43.","journal-title":"Clin Pharmacol Ther."},{"key":"466_CR62","unstructured":"Summary of product characteristics: Adenuric 80 mg film coated tablets. European Medicines Agency; 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000777\/WC500021812.pdf . Accessed 10 Mar 2016."},{"issue":"11","key":"466_CR63","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00296-015-3355-5","volume":"35","author":"F Perez-Ruiz","year":"2015","unstructured":"Perez-Ruiz F, Chinchilla SP, Atxotegi J, Urionaguena I, Herrero-Beites AM, Aniel-Quiroga MA. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. Rheumatol Int. 2015;35(11):1857\u201361.","journal-title":"Rheumatol Int."},{"key":"466_CR64","doi-asserted-by":"crossref","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447\u201361.","DOI":"10.1002\/acr.21773"},{"key":"466_CR65","unstructured":"Signal: febuxostat and hepatic failure. World Health Organization (WHO). WHO Pharmaceuticals Newsletter. 2013;2:11\u201312. http:\/\/www.who.int\/medicines\/publications\/NewsletterNo2_2013EC.pdf . Accessed 10 Mar 2016."},{"issue":"2","key":"466_CR66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s13730-014-0109-2","volume":"3","author":"K Ito","year":"2014","unstructured":"Ito K, Ueda Y, Miyazawa H, Kaku Y, Hirai K, Hoshino T, et al. Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis. CEN Case Reports. 2014;3(2):158\u201361.","journal-title":"CEN Case Reports."},{"key":"466_CR67","unstructured":"Febuxostat safety reports. Pharmacovigilance Insight. Springer 2013. Available from: http:\/\/adisinsight.springer.com . Accessed 18 June 2014."},{"issue":"7","key":"466_CR68","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","volume":"4","author":"TM MacDonald","year":"2014","unstructured":"MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354.","journal-title":"BMJ Open."},{"issue":"1","key":"466_CR69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2012.04.011","volume":"164","author":"WB White","year":"2012","unstructured":"White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14\u201320.","journal-title":"Am Heart J."},{"issue":"9","key":"466_CR70","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","volume":"38","author":"S Chohan","year":"2011","unstructured":"Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957\u20139.","journal-title":"J Rheumatol."},{"issue":"5","key":"466_CR71","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/1060028014521389","volume":"48","author":"M Dore","year":"2014","unstructured":"Dore M, Frenette AJ, Mansour AM, Troyanov Y, Begin J. Febuxostat as a novel option to optimize thiopurines\u2019 metabolism in patients with inadequate metabolite levels. Ann Pharmacother. 2014;48(5):648\u201351.","journal-title":"Ann Pharmacother."},{"issue":"1","key":"466_CR72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0378-6323.74964","volume":"77","author":"R Kumari","year":"2011","unstructured":"Kumari R, Timshina DK, Thappa DM. Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 2011;77(1):7\u201315.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"466_CR73","unstructured":"Safety of medicines: febuxostat and agranulocytosis. World Health Organization. WHO Pharmaceuticals Newsletter. 2015;4:16. http:\/\/www.who.int\/medicines\/publications\/Pharm_Newsletter4_2015.pdf . Accessed 10 Mar 2016."},{"issue":"3","key":"466_CR74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jcpt.12057","volume":"38","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013;38(3):258\u201361.","journal-title":"J Clin Pharm Ther."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0466-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T11:36:28Z","timestamp":1749641788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0466-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0466-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}